Dr. Alexander Lyon is a Consultant Cardiologist at the Royal Brompton Hospital. Alex trained at Oxford University where he was awarded a first class degree and a clinical scholarship. Alex studied for his PhD in gene therapy for heart failure at Imperial College. His clinical interests are in the field of cardio-oncology (cardiovascular disease in cancer patients), heart failure, complex hypertension, Takotsubo syndrome and the effects of major stresses of the heart, and gene therapy for chronic heart failure.

Alex has been the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. The service was recently awarded a Gold Cardio-Oncology Centre of Excellence award from the International Cardio-Oncology Society in 2022, and he is the Director of the new Cardio-Oncology Centre of Excellence at the Royal Brompton Hospital.

Alex is a co-chair of the first ESC Cardio-Oncology Guideline which was presented and published in August 2022 which includes 272 new recommendations for the management of cardiovascular disease in cancer patients and survivors. The guideline has over 430,000 webpage views, 145,000+ downloads and 1350+ citations in the first 2 years since publication. He is also a co-author of the 2021 ESC guidelines for heart failure, 2021 BSE-BCOS guideline on echocardiography in cancer patients and the 2022 ESMO guideline on the diagnosis and management of immunotherapy-related toxicities.

Alex is a past chair of the European Society of Cardiology (ESC) Council of Cardio-Oncology (2022-2024), the past president of the British Cardio-Oncology Society, a board member of International Cardio-Oncology Society (ICOS), and he is the cardiology advisor to the charity Macmillan Cancer. Alex is a co-investigator of the first Leducq Cardio-Oncology Transatlantic Research Network funded from 2020-2025 ($6M). In 2017 Alex was co-chair of the Global Cardio-Oncology Summit which hosted 325 specialists from 33 countries at the Royal College of Physicians in London.

Alex has published over 240 scientific papers in peer-reviewed journals and Alex is a deputy editor of the European Heart Journal. His H-index is 69 and in 2023 he was identified as one of the top 50 most highly cited academic doctors in the UK in the last 10 years by the Web of Science.

MD, PhD
Clínica Universidad de Navarra, Pamplona, Spain

Education and Training
• Medical Degree, Universidad Autónoma de Madrid
• Doctorate in Medicine (PhD), Universidad Autónoma de Madrid
• Hematology and Hemotherapy Fellowship, Hospital Universitario La Paz, Madrid
• Fellowship in Lymphoma and Myeloma, Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, Texas (under the direction of Prof Fernando Cabanillas)

Professional Experience
• Section Head and Director of the Hematopoietic Transplant Program, Hematology Department, Hospital Universitario La Paz, Madrid
• Associate Professor of Medicine, Universidad Autónoma de Madrid
• Consultant, Department of Hematology and Hemotherapy, Clínica Universidad de Navarra, Pamplona, Spain (current)
• Professor of Medicine, Universidad de Navarra (current)

Research Activities
• Author of over 110 publications in peer-reviewed journals, including Journal of Clinical Oncology, Blood, British Journal of Haematology, Annals of Oncology, Haematologica, Cancer, Bone Marrow Transplantation, Blood Cancer Discovery, Lancet Haematology, Lancet Oncology, American Journal of Hematology, and Annals of Hematology
• Contributed to the editing of books (2) and book chapters (20) on lymphomas and lymphoproliferative disorders
• Principal investigator in 60 clinical trials

After graduating in Medicine in 2006, Pietro Ameri completed the residency and received his PhD in 2014 at the University of Genova, Italy. He is now Associate Professor in Cardiovascular Diseases at the University of Genova / IRCCS San Martino Policlinic Hospital, where he directs the Heart Failure and Pulmonary Hypertension clinical programs, as well as a translational research laboratory. Prof. Ameri's primary interest is heart failure. He is also involved in cardio-oncology, especially with respect to the interplay between heart failure, cancer, and anti-cancer therapies. If he was asked to bring a book, a movie, and a song with him on a desert island, today he would pick The catcher in the rye, The big Lebowski, and Hey you.

Short CV:
Degree in Medicine in University of Navarra (2002-2008). Hematology Residency in Gregorio Marañón General University Hospital in Madrid (2009-2013). Consultant in the Hematology Department of Son Espases University Hospital from 2013 until now. Professional experience abroad focused in transplant field in Long Term Follow Up Program in Fred Hutchinson Cancer Center, Seattle-USA (2016). PhD degree from the University of the Balearic Islands (2019). Active member of the Hematological Neoplasms Group of the Balearic Research Institute (IdISBa). Associate professor of the Faculty of Medicine in Balearic University. Lymphoid Working Group Coordinator from the Spanish Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (GETH-TC) and active member of the Spanish Group for Lymphoma and Autologous Transplantation (GELTAMO).

Social network account:
Twitter: @leyrebento

Jutta Bergler-Klein, Prof. of Med., FESC, FHFA, FEACVI, is heading the cardiac outpatient clinic at the Dept. of Cardiology at the Medical University of Vienna, as well as founder and head of the first Austrian Cardio-Oncology unit. Currently, she is ESC Council of Cardio-Oncology ex officio Board member. In the ESC Cardio-Oncology 2022 guidelines, she is coauthor (2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) https://doi.org/10.1093/eurheartj/ehac244) , and task force member of the ESC cardio-oncology curriculum under development. Her scientific interests are cardio-oncology, valve disease and radiation impact, aortic stenosis, cardiac biomarkers, heart failure. She is former chair of the Working group on Echocardiography of the Austrian Society of Cardiology, and was Nucleus member of the ESC Valvular WG. She was nucleus member of the Study Group on Cardio-Oncology of the ESC HFA.

Twitter @BerglerKlein

Linkedin Jutta Bergler-Klein https://at.linkedin.com/in/jutta-bergler-klein-36b889a3

Facebook Jutta Bergler

Dr. Daniela Cardinale graduated from the University of Milan in 1987 and specialized in Cardiology (Milan 1992). She holds a PhD in Cardiovascular Physiopathology from the same University (2009). She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan, where she has been working since 1994. She has previously worked at the Operative Unit of Intensive Cardiac Care of the Centro Cardiologico Monzino (1987-1990) and at the Cardiology Division of S. Raffaele Hospital of Milan (1990-1994). Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment. On 31/10/2018 she achieved the National Scientific Qualification as Associate Professor in the Italian higher education system for the disciplinary field of Cardiovascular and Respiratory diseases. She is a fellow of the European Society of Cardiology.

Milan, 13 July 2023

Dr Raul Cordoba is Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital, Madrid, Spain. He obtained his Bachelor of Medicine degree from the Autonomous University of Madrid and went on to specialise in haematology at the University Hospital La Princesa, Madrid. He first started his research in the field of lymphoid neoplasms, achieving his Master’s degree in Molecular Oncology from the Spanish National Cancer Research Centre, Madrid, and his PhD from the Department of Medicine at the Autonomous University of Madrid.Dr Cordoba participated in the first edition of the Certificate of Competence in Lymphoma at Ulm, Germany. He is currently the Principal Investigator for the Haematology Programme of START Madrid-FJD, a unit dedicated exclusively to Phase I trials in oncology.He is the chair of the EHA-Scientific Working Group of “”Aging and Hematology”” of the European Hematology Association (EHA). He has participated as a co-author of the 2022 Guidelines of Cardio-Oncology of the European Society of Cardiology.

Head of the Medical Oncology Section of the Hospital Universitario La Paz in Madrid and Director of the Innovation Unit of the Hospital La Paz Institute for Health Research - IdiPAZ. Associate Professor of Oncology at the Autonomous University of Medicine of Madrid and Co-Director of the Chair of Innovative Medicine.
The main areas of scientific and healthcare interest are focused on the molecular biology of lung cancer and other thoracic tumors, the study of predictive factors of response to cancer treatments using high-throughput techniques and the study of etiopathogenic factors of the disease and supportive care. In particular, he has participated in the clinical development of EGFR and ALK inhibitors, antiangiogenic drugs and immunotherapy in lung cancer. Dr. de Castro has published more than 200 articles in international journals and is a member of ASCO, IASLC and ESMO. He is currently secretary of the board of SEOM (Spanish Society of Medical Oncology).

Social media:
Twitter: @javierDcastro
Instagram: javierdecastro_oncologo
Linkedin: linkedin.com/in/javier-de-castro

Victoria Delgado is Head of the Cardiovascular Imaging section of the Heart Institute (iCor) at the University Hospital Germans Trias i Pujol with specific focus on multimodality imaging. She obtained the Medical degree at the University of Barcelona and specialized in Cardiology at Hospital Clinic of Barcelona. She obtained the PhD with cum laude at the University of Leiden (The Netherlands) and worked as Senior Cardiology Consultant at the Leiden University Medical Center for 13 years.
She is currently the President-Elect of the European Association of Cardiovascular Imaging. She has served as councilor of the European Society of Cardiology board from 2020-2022 and has been heavily involved in numerous committees of the Society such as member of the EuroObservational Regristry Programme and committee of the Clinical practice Guidelines.
She is Senior Editor of Circulation and board member of various international peer-reviewed Journals.
She is Scientific Advisory Board member of the European Cardiovascular Research Institute and currently holds the position of President of the Scientific Commission of the Fund for Scientific Research (F.R.S.–FNRS).

SoMe: @VDelgadoGarcia (twitter)

Prof. Dimitrios Farmakis, MD, PhD, FESC, FHFA

National and Kapodistrian University of Athens Medical School, Athens University Hospital Attikon, Athens, Greece.

Prof. Farmakis’ main clinical and research focus is heart failure, cardio-oncology and haemoglobinopathy-associated cardiovascular disease. He has a strong publication record in highly-ranked journals (283 PubMed articles, total citations, 22124; h index, 65) and textbooks (72 chapters, 5 complete textbooks). He has received grants for research projects and has served as primary investigator or steering committee member in research programs funded by the European Commission. He also sits on editorial boards of international medical journals and on several scientific or advisory committees, while he serves as a reviewer for many highly-rated journals. Among others, he is the Chairman of the European Society of Cardiology (ESC) Heart Failure Association Study Group on Cardio-Oncology, President of the Hellenic Society of Cardiology Working Group on Oncocardiology and member of ESC guidelines taskforces on heart failure and cardio-oncology. He is also a medical advisor to Thalassaemia International Federation (TIF) and editor of the recent TIF guidelines for transfusion-dependent thalassaemia. He has received awards and distinctions from the Universities of Athens and Patras, Harvard Medical School, American Heart Association, United Arab Emirates government and others.

Group leader of Cardiovascular Physio-pathology at Institute of Research University Hospital La PAZ, IdiPAZ

Social media:
Twitter: @Mfvlorenzo; @IdiPAZScience

Alessandra Ghigo, PhD
Associate Professor of Applied Biology
University of Torino
Department of Molecular Biotechnology and Health Sciences
Torino (ITALY)

Alessandra Ghigo is Associate Professor of Applied Biology at the Department of Molecular Biotechnology and Health Sciences of the University of Torino. She is best known for her work on the crosstalk between phosphoinositide 3-kinase (PI3K) and cyclic nucleotide signaling pathways in heart failure and arrhythmias. Her recent interest is the comprehension of the molecular mechanisms underlying the cardiotoxicity of anti-cancer therapies, with a major focus on the contribution of PI3K enzymes. She is author of more than 90 publications in highly reputed journals, including Science, Science Translational Medicine and Circulation. She is invited speaker in prestigious conferences including meetings of the American Heart Association, the European Society of Cardiology and the International Society for Heart Research. She is co-founder and Scientific Advisor of Kither Biotech, a biotechnology company developing PI3K inhibitors for the treatment of respiratory diseases.

Linkedin page: https://www.linkedin.com/in/alessandra-ghigo-5599b92b/

Since 2004 she is heading of the Human Genotyping Unit, as part of the Spanish National Genotyping Center (www.cegen.org). Her research activity at the CNIO is focused on the identification of genetic markers influencing cancer susceptibility and drug response. Gonzalez-Neira´s work is focused on breast cancer, but extends to several other cancer types such childhood cancers, lung cancer and more recently testicular cancer. She has been involved since 2006 in the Breast Cancer Consortium (BCAC) and in the last ten years she has been involved with other BCAC partners as work package leader in two European projects focused on the identification of breast cancer genes: the Collaborative Oncological Gene-environment Study (COGS) and the Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) project. Using genotyping and next generation sequencing technologies, these two projects, which involved the analysis of thousands of samples from different countries, have allowed identifying many relevant risk alleles and results have been published in high-impact journals.

Currently, she is executive broad Member of the Spanish Society for Pharmacogenetics and Pharmacogenomics (SEFF) and the National Representative and Board Member in the European Association for Predictive, Preventive and Personalized Medicine (EPMA).

She plays an important role in fundraising through national and international competitive projects and in the communication and establishment of effective collaborations with other researchers and institutions. In recent years, she has focused her efforts to facilitate the incorporation of genomics into clinical practice, working on the implementation of the genetic information in the NHS

Borja Ibáñez (Madrid, 1975) combines research activities as Scientific Director of the Spanish National Center for Cardiovascular Research (CNIC) with clinical activities as interventional cardiologist at the University Hospital Fundación Jiménez Díaz.

He was trained in Spain and in USA (Mount Sinai Heart, NY). His research is at the verge of basic and clinical arena, mainly in the fields of MI, heart failure and lately to cancer therapy-induced cardiotoxicity. He is the co-PI of the large PESA project, focused on primary prevention of atherosclerosis.

He is PI of several multicenter clinical trial. He served as the Chairperson of the 2017 European Society of Cardiology (ESC) STEMI Clinical Practice Guidelines and is Chairperson of the forthcoming ESC guidelines for Acute Coronary syndromes.

He is PI coordinator of several national and international projects, including H2020-funded grants, highlighting an active ERC consolidator grant called “MATRIX” (Novel mitochondria-targeted therapies for anthracycline-induced cardiotoxicity), and a H2020-HEALTH project called “RESILIENCE”.

He has published more than 350 scientific publications in high-impact journals. His H-index (scholar) is 73, and his works have received more than 50,000 citations.

He has received numerous awards for his scientific merits, including the Banco de Sabadell, Constantes y Vitales, Princesa de Girona, and Fundación Jesús Serra among others.

twitter: @borjaibanez1

Teresa López-Fernández is a clinical investigator and senior consultant cardiologist at the University Hospital of La Paz in Madrid, Spain. Dr López-Fernández specialises in cardiac imaging and cardio-oncology. Dr López-Fernández coordinates the Cardio-Oncology Clinic at the University Hospital of La Paz. She is the founder and president of the Spanish Cardio-Oncology Working Group of the Spanish Society of Cardiology (SEC). She is also vice-president of the International Cardio-Oncology Society (ICOS) and was elected president of the ESC Council for Cardio-Oncology. Dr López-Fernández is co-chair of the ESC Guidelines on Cardio-Oncology 2022. Her current research interests focus on the diagnosis and prevention of cardiotoxicity.

Pilar Martín Fernández is Assistant Professor at the Spanish National Cardiovascular Research Center (CNIC) in Madrid. Dr. Martin leads a line of research in the field of Cardio-Immunology, focused on the role of T cells and microRNAs in the pathophysiology of myocarditis, atherosclerosis and myocardial infarction in preclinical models and humans. Her contributions to the cardio-immunology field as a senior author have been published in high-impact journals, including the New England Journal of Medicine, Circulation, the Journal of Clinical Investigation, European J Heart Failure, or the Journal of Autoimmunity. Her group has developed two patents: "Method for diagnosing cardiomyopathies" and "Kit for the diagnosis of acute myocarditis".

Social networks:
Twitter: @PilarMartinFern
https://orcid.org/0000-0002-2392-1764

Wouter C. Meijers MD PhD FESC FHFA
(Experimental) Cardiology Department
Erasmus MC, Rotterdam, The Netherlands

Dr. Wouter C. Meijers obtained his medical degree at the Maastricht University. After which he was granted a PhD position at the (Experimental) cardiology department of prof. de Boer and prof. van Veldhuisen, which he later on defended cum laude. His translational studies focused on heart failure and more specifically on cardio-oncology. He pioneered on the reciprocal relationship between cancer and heart failure. Furthermore, he co-founded the more specialized field of cardio-immuno-oncology. He obtained several national and international grands and awards which helped him to pursue his research career. He was the first Dutch cardiologist in training whom performed a post-doctoral fellowship in the field of cardio-oncology at the Vanderbilt University Medical Center in Nashville, Tennessee, USA with prof. Moslehi. He is currently fellow of both the European Society of Cardiology as the Heart Failure Association. He recently transferred within the Netherlands to Rotterdam, the Erasmus Medical Center to further train himself within (advanced) heart failure and cardio-oncology and to further expand his own research group.

Twitter: @WCFWMeijers

Cardiology Faculty at University Hospital Puerta de Hierro Madrid since 2015. Cardio-Oncology Coordinator at this centre since 2016
Member of The Advanced Heart Failure and Heart Transplant Unit.
Member of the Cardio-Oncology working group at the Spanish Society of Cardiology and of the International Cardio-Oncology Society

Twitter: @Cristina_Mitroi

Pedro Moliner, MD, PhD. Cardiologist. L’Hospitalet de Llobregat, Barcelona.
Head of the Cardio-Oncology Unit in Bellvitge University Hospital with the Catalan Institute of Oncology. Cardiology Consultant at the South Metropolitan Barcelona Integrated Heart Failure Programme. Postdoctoral researcher in the BIOHEART Cardiovascular Disease Research Group. IC-OS Board Certification. Coordinator of the Cardio-Oncology Group of the Catalan Society of Cardiology. Member of the Cardio-Oncology working group of the Spanish Society of Cardiology and the Council of Cardio-Oncology of the European Society of Cardiology. Member of the editorial board of the European Journal of Internal Medicine. Collaborating professor in the Medicine degree at University of Barcelona.

Twitter: @PeterMoliner
Linkdin: linkedin.com/in/pedro-moliner-borja-01761895

Tienush Rassaf is Director and Chair of the Department of Cardiology and Vascular Medicine at the University Hospital Essen, Germany, and Vice-Dean of Research of the Medical Faculty in Essen. Prof Rassaf is an interventional cardiologist with a research focus on cardioprotection in acute myocardial infarction and myocardial ischemia/reperfusion- injury. He is founding member and has been chairmen of the working group ‘Cardiooncology’ of the German Cardiac Society (DGK). On of his current research interests focus on the prevention of cardiotoxicity.

Twitter: @TRassafMD

Thomas Suter is board-certified in cardiology and internal medicine and the head of the Department of Internal Medicine at Lindenhofgruppe in Bern, Switzerland. In addition, he leads the Cardio-Oncology Service and is a member of the section for heart failure and cardiac transplantation at the University Hospital Bern. He received his medical degree from the University of Zurich and took residency training in internal medicine and cardiology at University Hospital Zürich, Boston University Medical Center and Brigham and Women’s Hospital, Boston MA. During his cardiology training, he specialized on heart failure and cardiac transplantation. His clinical research during the past 20 years focused on the investigation of cardiovascular side effects of cancer therapeutics. He currently serves as the chair of the Council on Cardio-Oncology of the European Society of Cardiology and on several steering committees of multinational cancer trials. Furthermore, he is directing a basic research lab in which he investigates mechanisms of chemotherapeutic-associated cardiotoxicity. His publications include over 100 articles on heart failure, cancer drug-associated cardiovascular side effects and general cardiology and more than 20 books on general and internal medicine.

Selected publications:
Cardio-oncology in clinical studies and real life. Dent SF, Suter TM, Minotti G et al. Semin Oncol. 2019 Dec;46(6):421-425

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
Lenihan D, Suter T, Baselga J et al. Ann Oncol. 2019 Jun 1;30(6):1021.

Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018'. Anker MS, Suter T, Lyon AR et al. Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. ESC Heart Fail. 2018 Dec;5(6):1083-1091

Cardio-Oncology Services: rationale, organization, and implementation.
Lancellotti P, Suter TM, Asteggiano R et al. Eur Heart J. 2019 Jun 7;40(22):1756-1763.

Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Ameri P, Suter T, Tocchetti CG et al. Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Eur J Heart Fail. 2018 May;20(5):879-887

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Ponde N, Suter T, de Azambuja E et al. Breast Cancer Res Treat. 2018 Apr;168(3):631-638.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. von Minckwitz G, Suter T, Baselga J et al. N Engl J Med. 2017 Jul 13;377(2):122-131.

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. Zardavas D, Suter TM, de Azambuja E et al. J Clin Oncol. 2017 Mar 10;35(8):878-884.

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Zamorano JL, Lancellotti P, Suter TM et al.; ESC Scientific Document Group. Eur Heart J. 2016 Sep 21;37(36):2768-2801.

Prof. Carlo Gabriele Tocchetti is currently Associate Professor of Medicine in the Department of Translational Medical Sciences, Federico II University, Naples, Italy since 2014, where he is Director of the Internal Medicine Unit for cancer patients and has established himself as a HF basic and clinical investigator. Prof Tocchetti is President, International Cardio-Oncology Society (ICOS) Italy Chapter, Fellow of the HFA, Chair of the Basic Science Section of the HFA, and Board member of the ESC Council on Cardio-Oncology.

The main goal of his lab is to explore pathophysiologic mechanisms and therapeutic targets in cardiac dysfunction, with a particular interest on post-ischemic HF, genetic and inflammatory cardiomyopathies, Pulmonary Hypertension and RV dysfunction, and HF due to antineoplastic therapies, including novel anticancer immunotherapies and biologic drugs employed in inflammatory diseases.

Professor Peter van der Meer, MD, PhD
University Medical Center Groningen, Netherlands
Peter van der Meer is a cardiologist, chair of the Department of Experimental Cardiology and director of the Coronary Care Unit at University Medical Center Groningen. He is also a Professor of Heart Failure and Translational Cardiology at the University of Groningen.
Professor van der Meer received both his MD and PhD cum laude from the University of Groningen, and completed a postdoctoral fellowship at Harvard Medical School, Boston, MA, USA. He authored >300 manuscripts, has an H-index of 77 and was member of the 2022 ESC CardioOncology guidelines. He is a member of several steering committees of large phase 3 trials. His research is funded by national and international grants including an ERC StG and CoG grant. His research group consists of PhD students and post-docs with various backgrounds (biologists, medical doctors and biomedical-engineers) working on translational research topics to bridge the gap between bench and bedside. Professor van der Meer’s research focusses on understanding the susceptibility to develop heart failure and on exploring novel treatment targets and therapies.

Twitter: @p_van_der_meer

Dr. -Nicolás MD, PhD. Clinical cardiology and heart failure specialisth. Coordinator of the Cardio-oncology multidisciplinary group at University Hospital Gregorio Marañón in Madrid. Member of the ICOS advocacy commettee, Cardio-oncology working group of Spanish Society of Cardiology and member of the ESC cardio-oncology council.

SoMe: @Edu